Initiate critical clinical trial with ZG006 for injection and complete the first subject enrollment.

On September 16th, Zejing Pharmaceutical announced that the company has received feedback from the National Medical Products Administration Drug Evaluation Center regarding the conditional approval for the marketing qualifications of the company's investigational product ZG006 for injection. Based on the safety and efficacy data of ZG006 for injection and the target population, the Center for Drug Evaluation (CDE) has approved the conduct of key clinical trials for ZG006 for injection. The company is actively advancing the key clinical trials of ZG006 for injection in the proposed indication, and has recently completed the enrollment of the first subject. ZG006 for injection has been included in the list of breakthrough therapies by CDE, indicated for the treatment of advanced small cell lung cancer patients who have previously received platinum-based chemotherapy and at least one other systemic treatment and have experienced recurrence or progression.